

European Commission Initiative on Breast Cancer

Annual Declaration of Interests (ADoI)

Name: Giorgio Stanta - 2021

[Please copy rows as needed for subsequent or parallel activities of the same nature]

[If it is not clear to you under which category of the form to declare an interest, you can declare it under "Other"].

Nature of activities	Period	Entity	Subject matter
1. Ownership or financial investments, including shares	MM/YYYY – MM/YYYY	Companies or organisations in which the financial interest is placed	[Relevant field of activity]
2. Membership of a managing body or equivalent structure	MM/YYYY – MM/YYYY	- Name - Location - Nature: public, private, etc.	Function of institution: Function of expert: Link to website of institution:

Nature of activities	Period	Entity	Subject matter
3. Membership of another scientific advisory body	07/2012 – today	<ul style="list-style-type: none"> - Organisation of European Cancer Institutes (OECI) - Brussels - Nature: public 	<p>Function of body: The OECI is a non-government, non-profit Organisation founded in Vienna in 1979 with the primary objectives to improve communication and to bring together the cancer research and care institutions of the European Union, in order to create a critical mass of expertise and competence.</p> <p>Function of expert: Chair of the Biobanking and Molecular Pathobiology WG</p> <p>Link to website of body: www.oeci.eu</p>
	09/2012 – today	<ul style="list-style-type: none"> - European Society of Pathology (ESP) - Brussels - Nature: public 	<p>Function of body: The ESP is a society bringing together most European pathologists. It has as its primary aim the promotion of high quality diagnostic practice, applied and translational research and under- and postgraduate education in the field of human pathology.</p> <p>Function of expert: Chair of the Molecular Biology WG</p> <p>Link to website of body: www.esp-pathology.org</p>
	01/2015 – today	<ul style="list-style-type: none"> - Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-ERIC) - Graz, Austria - Nature: public 	<p>Function of body: BBMRI-ERIC will increase efficacy and excellence of European bio-medical research by facilitating access to quality-defined human health/disease-relevant biological resources.</p> <p>Function of expert: Chairman of the Archive Tissue Working Group</p> <p>Link to website of body: http://bbmri-eric.eu/</p>
	12/2019 -	<ul style="list-style-type: none"> - European Cancer Patients Coalition (ESPC) 	<p>Scientific Advisory Board</p>
4. Employment	11/2018 – today	<ul style="list-style-type: none"> - University of Trieste -Type: public 	<p>Contract Professor of Pathology. Molecular diagnostics, histopathology, molecular pathology teaching, clinical research.</p>

Nature of activities	Period	Entity	Subject matter
5. Consultancy/Advisory	10/2014 – today 07/2019 – today	- Centro di Riferimento Oncologico (CRO), Aviano (Italy). -Type: public -Novartis – Melanoma European Multidisciplinary Consultancy Board	Consultant for Molecular Pathology in clinical research and diagnostics and for biobanking. Organization of the Italian network of archive tissue biobanks (NIPAB). Organization of Expert Centre for Molecular Pathology in archive tissues. Define priority actions: melanoma patient advocacy academy; interactive visualization of the patient pathway; pathology coming our of the lab.
6. Influence on definition of research priorities			<p>1.Improvement of clinical research, validation and quality of biomarkers.</p> <p>2.Member of the Committee of CEN (European Committee for Standardization) for Molecular in-vitro diagnostic examinations.</p> <p>3.Technical Working Groups: -DNA and RNA extraction, SOPs and IQC in ATs (person in charge) -Proteomics SOPs in ATs (participant) -Pre-analytical conditions in tissues (participant) -Tumour heterogeneity (person in charge)</p> <p>4.Diagnostics (Molecular Diagnostics in Clinical Tissues; Histopathological Diagnostics).</p> <p>5.Histopathology: histopathological diagnostics and immunohistochemistry.</p> <p>6.Molecular Diagnostics: molecular analysis in clinical tissues (ESP).</p> <p>7.Epidemiology: past experience in tumour registries.</p>

Nature of activities	Period	Entity	Subject matter
7. Research grants and other funding	03/2007 – 03/2010	- IMPACTS (Archive Tissues : Improving Molecular Medicine Research and Clinical Practice), Coordination Action within the 6th Framework Programme of the European Commission, Contract Number : 037211, Coordinator : Giorgio Stanta, University of Trieste. -Type: public - EUR 600.000	- Molecular method validation and standardization for AT; dissemination of standardized methods for functional genomics and proteomics at the European level with good practice rules; preparation of future perspectives at the clinical, research and technology level; establishment of tentative bioethics common guidelines for utilization of human archive tissues in multicentric research; availability of multicentric tissues banks for translational research; promotion of technology innovation and industrial collaboration.
	10/2006 – 10/2009	-ACUME2 (Interfacing Sciences, Literature and Humanities), European Thematic Network Projects, FP6, Coordinator : Vita Fortunati, University of Bologna. Giorgio Stanta was a partner. -Type: public	-To highlight the body conceptualization and to underline relationships with the juridical, cultural, social level; to try to stimulate a dialogue between researchers with different background; to encourage to set up effective solutions for new bioethical treatments, concerning the body and its parts (bank of biological materials).

Nature of activities	Period	Entity	Subject matter
	01/2016 – 01/2021	<p>-HERCULES (Comprehensive characterisation and effective combinatorial targeting of high-grade serous ovarian cancer via single-cell analysis), Call: H2020-PHC-2015-two-stage, Topic: PHC-02-2015, Type of action: RIA, Proposal number: 667403-2. Coordinator: Sampsa Hautaniemi, University of Helsinki. Giorgio Stanta is a partner. -Type: public - EUR 6.000.000</p>	<p>-The goal of this multidisciplinary project is to comprehensively characterise high-grade serous ovarian cancer (HGS-OvCa) at single-cell level, identify the best combination of drug combination to kill HGS-OvCa populations and commercialise a predictive biomarker kit for finding the right therapeutic regimen to the right patient. The specific target for Stanta's group is verification and validation of biomarkers in clinical material.</p>
	01/2017 – 01/2021	<p>-SPIDIA4P (SPIDIA for Personalized Medicine - Standardisation of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine), Call: H2020-SC1-2016-RTD, Topic: SC1-HCO-02-2016, Type of action: CSA, Proposal number: 733112. Coordinator: Uwe Oelmüller, Qiagen GmbH. Giorgio Stanta is a partner. -Type: private - EUR 1.999.972,50</p>	<p>-SPIDIA4P aims to generate and implement a comprehensive portfolio of 22 pan-European pre-analytical CEN/Technical Specifications and ISO/International Standards, addressing the important pre-analytical workflows applied to personalized medicine.</p>
	2017 - 2019	-MEMS	<p>Collaborative Project on cutaneous melanoma characterization in alpine and seaside areas.</p>
	11/2019 - 2024	-INSTAND-NGS	<p>Collaborative Project – Pre-Commercial Procurement. NGS sequencing is widely used for diagnostics and clinical research and there is a high number of commercial items on the market. This project aims at evaluating these items considering pre-analytics, techniques, interpretation and reporting.</p>


Nature of activities	Period	Entity	Subject matter
8. Principal investigator or investigator			<ul style="list-style-type: none"> -Organization of rapid verification and validation of biomarkers. -Standardization of molecular oncology procedures for archive clinical tissues. -Tumour heterogeneity in clinical research and diagnostics. -Pre-analytical conditions of clinical biological material. -Development of molecular analysis methods and kits for clinical tissues.
9. Intellectual property rights (IPR)	MM/YYYY – MM/YYYY		<ol style="list-style-type: none"> 1.WO patent WO/2001086,288 (wipo.int) "Kit for early diagnosis for bladder cancer" 2.WO patent PCT/IB2010/052763(wipo.int) "REQ1 as specific anticancer agent" 3.PCT/EP2012/067445 "Prognostic marker for prostatic cancer" presented on 6th September 2012. 4. PCT/EP2013/076772; WO 2014/095766 A1; Publication 26th June 2014. Patent on predictive biomarker for the use of EGFR inhibitor drugs in colorectal cancer, in collaboration with the University of Graz. In extension with a U.S. company.
10. Other membership or affiliation	MM/YYYY – MM/YYYY	<ul style="list-style-type: none"> - Name, Place -Type: public, private, etc. 	[Describe activity, function, website]
11. Interests of others	MM/YYYY – MM/YYYY		[Describe activity, function]
12. Other	MM/YYYY – MM/YYYY	<ul style="list-style-type: none"> - Name, Place -Type: public, private, etc. 	[Describe activity, function, website]

I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge.

Should there be any change to the above information, I will promptly notify the responsible service of the Commission and complete a new DoI form including the changes.

Done at: Trieste

Date: 10th January 2021

A rectangular box containing a handwritten signature in black ink. The signature is written in a cursive style and reads "Giorgio Stautu".

Signature: _____